Articles - Page 36 of 92 - Drugs in Context

Bispecific antibodies for non-Hodgkin’s lymphomas and multiple myeloma

Omar Castaneda-Puglianini, Julio C Chavez

Article Type

Review

Published

21 Sep 2021

This article is a narrative review of the most current data on bispecific antibodies in B cell non-Hodgkin’s lymphoma and multiple myeloma.

Transdermal buprenorphine for pain management in children

Giorgio Attinà, Alberto Romano, Silvia Triarico, Stefano Mastrangelo, Palma Maurizi, Antonio Ruggiero

Article Type

Review

Published

14 Sep 2021

This review aims to analyse the clinical advantages of transdermal buprenorphine in the paediatric population and the possible side effects registered in daily clinical practice.

Moving from the stratification of primary and secondary prevention of cardiovascular risk in diabetes towards a continuum of risk: need for a new paradigm

Xavier Garcia-Moll, Vivencio Barrios, Josep Franch-Nadal

Article Type

Commentary

Published

18 Aug 2021

This article discusses how patients with diabetes should be treated
according to their CV risk considered as a continuum and not simply as falling within primary or secondary prevention.

Response to ‘Presentation and pathophysiology of neuro-COVID’

Daniele Orsucci, Marco Vista

Article Type

Letter-to-the-Editor

Published

16 Aug 2021

Letter to the Editor in response to Finsterer J, Scorza FA, Scorza CA. Presentation and pathophysiology of neuro-COVID. Drugs Context. 2021;10:2021-6-5

Presentation and pathophysiology of neuro-COVID

Josef Finsterer, Fulvio Alexandre Scorza, Carla Alexandra Scorza

Article Type

Letter-to-the-Editor

Published

12 Aug 2021

Letter to the Editor commenting on Orsucci D, Caldarazzo Ienco E, Nocita G, Napolitano A, Vista M. Neurological features of COVID-19 and their treatment: a review. Drugs Context. 2020;9:2020-5-1.